Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04853186
Other study ID # 2104-WT
Secondary ID 215689/Z/19/Z
Status Recruiting
Phase
First received
Last updated
Start date May 11, 2021
Est. completion date June 2024

Study information

Verified date April 2023
Source Epicentre
Contact Anais BROBAN
Phone +33140215429
Email anais.broban@epicentre.msf.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol. The evidence generated from this project will be key to develop future strategies regarding cholera vaccine use in endemic settings, including places with higher burden in terms of cholera mortality.


Description:

The project will comprise three different components: 1. Clinical cholera surveillance to measure cholera diseases incidence in selected African hotspots targeted by vaccination. 2. Serial serological surveys to measure the prevalence of recent cholera infection (within the last 12 months). 3. Identification and follow up of individuals with positive V. cholerae shedding (symptomatic or asymptomatic) among sero-survey participants and among household members of cholera confirmed cases. The present protocol relates to the setup of clinical surveillance and the follow up of individuals with positive V. cholerae shedding identified through clinical surveillance, in DRC. This protocol will allow us to assess if a large vaccination campaign reaching high coverage in cholera hotspot in Africa can allow sustained control of cholera for at least two years, by fulfilling the following specific objectives: - To measure cholera incidence rates following the mass vaccination campaign in two cholera hotspots in Africa. - To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment. - To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household. - To describe the global genetic diversity of V. cholerae strains in the study areas and within households affected by cholera. - To develop sustainable surveillance methods that could be applied in other hotspots in Africa and elsewhere aiming to monitor the impact of the cholera control program.


Recruitment information / eligibility

Status Recruiting
Enrollment 6000
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility For Surveillance in study CTCs Inclusion Criteria: - All patients presenting at the time of the study to any selected Cholera Treatment Center/Cholera Treatment Unit (CTC/CTU), matching the case definition and giving his/her consent (or assent for children 8 to 17 years old) to participate in the study will be eligible. Exclusion Criteria: - Patients who decline to participate will be excluded from the study. Follow up of individuals with active cholera shedding: Inclusion Criteria: 1. present to any selected CTC/CTU, match the case definition, participate to the clinical surveillance activity and test positive to RDT OR 2. Be a household member of a person respecting inclusion criteria 1. AND for whom the head of the household has provided verbal consent to participate AND giving his/her consent (or assent for children 8 to 17 years old) to participate in the study will be eligible. Exclusion Criteria: - Individuals who decline to participate will be excluded from the study, as well as households for whom the head of the household (and his or her representative) decline the participation of his/her household.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Congo, The Democratic Republic of the Anais Broban Goma

Sponsors (6)

Lead Sponsor Collaborator
Epicentre Grand Labo de Lubumbashi, Institut National de Recherche Biomédicale. Goma, République Démocratique du Congo, Médecins Sans Frontières, France, Ministry of Public Health, Democratic Republic of the Congo, Wellcome Trust

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome

Type Measure Description Time frame Safety issue
Primary To better characterize cholera transmission in cholera hotspot in Africa and assess the impact of a large vaccination campaign reaching high coverage on sustained control of cholera transmission for at least two years. Specific objectives 1 and 4 will be answered through the clinical surveillance activity, below referred to as "Surveillance in study CTCs", while 2 and 3 relate to the follow-up activity, below referred to as "Follow-up of individuals with active cholera shedding". 2 years
Secondary 1. To retrospectively study surveillance data, and prospectively measure cholera incidence rates of medically-attended confirmed cases following the mass vaccination campaign in two cholera hotspots in Africa. 2 years
Secondary 2. To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment. one year
Secondary 3. To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household. one year
Secondary 4. To describe the global genetic diversity of V. cholerae strains in the study areas and within households affected by cholera. 2 years
See also
  Status Clinical Trial Phase
Completed NCT01895855 - Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Phase 3
Completed NCT01339845 - Introduction of Cholera Vaccine in Bangladesh N/A
Recruiting NCT05829772 - Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
Completed NCT04760236 - Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shancholâ„¢ Phase 3
Recruiting NCT04326478 - Single Dose Azithromycin to Prevent Cholera in Children Phase 2
Recruiting NCT06104345 - Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines Phase 4
Completed NCT02928341 - Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo N/A
Completed NCT02864433 - Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
Recruiting NCT06003816 - Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI) N/A
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT04150250 - Cholera Anti-Secretory Treatment Trial Phase 2
Terminated NCT00624975 - Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Phase 2
Completed NCT00226616 - Zinc Supplementation in Cholera Patients Phase 3
Completed NCT03373669 - Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Phase 4
Completed NCT02094586 - A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults Phase 3
Completed NCT02100631 - A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Phase 3
Completed NCT01823939 - PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Phase 1
Completed NCT01365442 - Pilot Introduction of Oral Cholera Vaccine in Orissa, India N/A
Completed NCT00128011 - Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Phase 2
Completed NCT00672308 - Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Phase 2